Boston Scientific (NYSE:BSX) EVP Sells 5,000 Shares of Stock

Leslie Hanson
June 14, 2018

The 6 months bullish chart indicates low risk for the $44.09 billion company. For example, a projected EPS growth stands at 175.00% in this year, while for the next years it is estimated at 12.65%. The Higher end of the revenue forecast is $2.49 Billion, while the Lower end of the forecast is $2.46 Billion. The stock was last seen 2.96% higher, reaching at $31.95 on 06/08/2018. Trading on both stocks was halted just before 1 p.m. Monday, but neither company commented on merger rumors. Fox Run Management L.L.C. bought a new position in shares of Boston Scientific in the 4th quarter worth approximately $873,000. It has underperformed by 1.38% the S&P500. The medical equipment provider reported $0.33 EPS for the quarter, beating the consensus estimate of $0.32 by $0.01.

Boston Scientific has spent much of the past decade paying down debt from its 2006 purchase of Guidant Corp.

When a company is able to grow consistently in terms of earnings at a high compound rate have the highest likelihood of creating value for its shareholders over time. It provides consumer drones, including mini, AR, and bebop drones; commercial drones; handsfree kits, plug and plays, and infotainment products; Bluetooth, digital music, and infotainment solutions; and audio products and connected devices.

Investors sentiment decreased to 0.96 in Q1 2018. Its down 0.38, from 1.34 in 2017Q4. Butcher Arthur C also sold $225,413 worth of Boston Scientific Corporation (NYSE:BSX) on Thursday, May 10. Boston Scientific's stock didn't surpass its pre-Guidant price until 2016, but company executives say the post-Guidant "turnaround" is complete. The insider now directly owns 71,151 shares worth $2,273,274.

According to Finviz reported data, The SMA20 of the stock is at 5.2 percent, SMA50 is 9.07 percent, while SMA200 is 14.19 percent. NY lessened its holdings in shares of Boston Scientific (NYSE:BSX) by 43.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC.

The Return on Invested Capital (aka ROIC) for Boston Scientific Corporation (NYSE:BSX) is 0.703093. Private Wealth Prtnrs Ltd has 402,658 shares. 183,900 are owned by Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Mngmt Corporation. The ROIC Quality of Boston Scientific Corporation (NYSE:BSX) is 7.851977.

Boston Scientific (NYSE:BSX) EVP David A. Pierce sold 5,000 shares of the firm's stock in a transaction on Friday, June 1st.

Boston Scientific Corporation (NYSE:BSX) now has a Montier C-score of 5. This is calculated by taking weekly log normal returns and standard deviation of the share price over one year annualized.


In other news related to Micron Technology, Inc. stock, 81.72% shares of MU held by institutions. A rating of 1 or 2 would be indicating a Buy recommendation. M&T National Bank & Trust owns 105,697 shares. $2.26 million worth of Boston Scientific Corporation (NYSE:BSX) was sold by Fitzgerald Joseph Michael. The stock grabbed 65 new institutional investments totaling 20,299,737 shares while 70 institutional investors sold out their entire positions totaling 6,963,688 shares. $603,368 worth of stock was sold by Thepaut Eric Francis Yves on Thursday, May 17.

Boston Scientific Corporation (NYSE:BSX) has a 1.05994 50/200 day moving average cross value.

BSX has been the topic of a number of other reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and three have issued a strong buy rating to the company. Therefore 87% are positive.

However, Boston Scientific has not yet indicated its response, the WSJ reported. The firm earned "Overweight" rating on Monday, March 19 by Morgan Stanley. As per Wednesday, April 25, the company rating was maintained by Jefferies. The company was downgraded on Thursday, August 13 by TheStreet. The company was initiated on Friday, February 23 by Piper Jaffray. The company has an average rating of "Buy" and an average target price of $32.39. On Wednesday, April 25 the stock rating was maintained by Needham with "Buy". Boston Scientific's stock has run up 24.4% over the past 12 months, while Stryker shares hve climbed 21.9% and the S&P 500 has gained 14.4%. Stocks with an increasing (year over year) ratio may be moving to be more capital intensive and often underperform the market. Leerink Swann maintained it with "Outperform" rating and $33 target in Thursday, April 26 report.

Boston Scientific Corporation (BSX) stock moved up 5.20% in contrast to its 20 day moving average displaying short-term an upside movement of stock. Stifel Nicolaus has "Buy" rating and $3300 target.

Boston Scientific traded up $2.37, reaching $34.32, during midday trading on Monday, MarketBeat Ratings reports.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER